{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "CORVUS PHARMAC.  DL-,0001", "longName": "Corvus Pharmaceuticals, Inc.", "messageBoardId": "finmb_279359732", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "marketState": "REGULAR", "regularMarketChangePercent": 14.0127325, "regularMarketPrice": 1.79, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.847, "epsForward": -0.9, "epsCurrentYear": -1.07, "priceEpsCurrentYear": -1.6728971, "sharesOutstanding": 29282100, "bookValue": 1.205, "fiftyDayAverage": 0.843752, "fiftyDayAverageChange": 0.94624794, "fiftyDayAverageChangePercent": 1.1214763, "twoHundredDayAverage": 0.8430515, "twoHundredDayAverageChange": 0.94694847, "twoHundredDayAverageChangePercent": 1.1232392, "marketCap": 49926320, "forwardPE": -1.9888889, "priceToBook": 1.4854771, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.2 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1459317600000, "priceHint": 4, "regularMarketChange": 0.21999991, "regularMarketTime": 1683892036, "regularMarketDayHigh": 1.83, "regularMarketDayRange": "1.79 - 1.83", "regularMarketDayLow": 1.79, "regularMarketVolume": 14000, "regularMarketPreviousClose": 1.57, "bid": 1.86, "ask": 1.95, "bidSize": 400, "askSize": 400, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 1.83, "averageDailyVolume3Month": 254, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 1.2184, "fiftyTwoWeekLowChangePercent": 2.1315606, "fiftyTwoWeekRange": "0.5716 - 1.83", "fiftyTwoWeekHighChange": -0.04000008, "fiftyTwoWeekHighChangePercent": -0.021857968, "fiftyTwoWeekLow": 0.5716, "fiftyTwoWeekHigh": 1.83, "earningsTimestamp": 1683577800, "earningsTimestampStart": 1691438400, "earningsTimestampEnd": 1691784000, "trailingAnnualDividendRate": 0.0, "symbol": "C17.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "863 Mitten Road", "address2": "Suite 102", "city": "Burlingame", "state": "CA", "zip": "94010", "country": "United States", "phone": "650 900 4520", "website": "https://www.corvuspharma.com", "industry": "", "sector": "", "longBusinessSummary": "Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.", "fullTimeEmployees": 29, "companyOfficers": [{"maxAge": 1, "name": "Dr. Richard A. Miller M.D.", "age": 71, "title": "Co-Founder, Pres, CEO & Chairman", "yearBorn": 1951, "fiscalYear": 2022, "totalPay": {"raw": 306000, "fmt": "306k", "longFmt": "306,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Peter A. Thompson FACP, M.D.", "age": 62, "title": "Co-Founder & Independent Director", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": {"raw": 47000, "fmt": "47k", "longFmt": "47,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Leiv  Lea", "age": 68, "title": "Chief Financial Officer", "yearBorn": 1954, "fiscalYear": 2022, "totalPay": {"raw": 388731, "fmt": "388.73k", "longFmt": "388,731"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. William Benton Jones Ph.D.", "age": 56, "title": "Sr. VP of Pharmaceutical Devel.", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 346419, "fmt": "346.42k", "longFmt": "346,419"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. James T. Rosenbaum M.D.", "title": "Sr. VP of Research", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}